New tradition in biotechnology

Follow us

Multivalent Salmonella vaccines – Wellcome Trust-Funded Project

Multivalent Salmonella vaccines – Wellcome Trust-Funded Project

Salmonella are bacteria that cause life-threatening diseases in adults and children. The global estimated burden of typhoid fever is over 21M illnesses and 200,000 deaths with sustained high incidence in South East Asia and endemic/epidemic occurrence in Africa. Paratyphoid causes 5.4M illnesses worldwide. Invasive non-typhoidal serovars (iNTS) are a leading cause of lethal sepsis and severe relapsing infections in young children and immune-compromised individuals, especially in countries of the sub-Saharan African region with an estimated 3.8M illnesses, 680,000 deaths annually and very high case-fatality ratios (20%).

These diseases co-exist in many geographical areas, especially in Low and Middle Income Countries (LMIC). Therefore, a single vaccine against all the major Salmonella infections would be highly desirable.

The project, that will be performed as a collaboration between the University of Cambridge and AchilleS Vaccines, and funded by the Wellcome Trust, will use genetically engineered mOMV to target various salmonella-related infections in a single vaccine preparation. The vaccine will have the advantages of efficacy, multivalency, safety and low production cost and will therefore benefit both travelers and those who live in endemic areas.

This site is registered on as a development site.